ELSEVIED

Contents lists available at ScienceDirect

European Journal of Pharmacology

journal homepage: www.elsevier.com/locate/ejphar



Cytoprotection of human endothelial cells from menadione cytotoxicity by caffeic acid phenethyl ester: The role of heme oxygenase-1

Xinyu Wang ^{a,b}, Salomon Stavchansky ^a, Baiteng Zhao ^{a,b}, James A. Bynum ^b, Sean M. Kerwin ^c, Phillip D. Bowman ^{b,*}

- ^a Pharmaceutics Division, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, USA
- ^b US Army Institute of Surgical Research, San Antonio, Texas 78234, USA
- ^c Division of Medicinal Chemistry and Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, Texas 78712, USA

ARTICLE INFO

Article history:
Received 11 March 2008
Received in revised form 14 May 2008
Accepted 2 June 2008
Available online 8 June 2008

Keywords:
Caffeic acid phenethyl ester
Cytoprotection
Oxidative stress
Human endothelial cell
Heme oxygenase-1
Gene expression analysis

ABSTRACT

Caffeic acid phenethyl ester (CAPE), derived from various plant sources, has been shown to ameliorate ischemia/reperfusion injury *in vivo*, and this has been attributed to its ability to reduce oxidative stress. Here we investigated the cytoprotection of CAPE against menadione-induced oxidative stress in human umbilical vein endothelial cells (HUVEC) to evaluate potential gene expression involvement. CAPE exhibited dose-dependent cytoprotection of HUVEC. A gene screen with microarrays was performed to identify the potential cytoprotective gene(s) induced by CAPE. Heme oxygenase-1 (HO-1) was highly upregulated by CAPE and this was confirmed with reverse transcriptase polymerase chain reaction (RT-PCR) and western blotting. Inhibition of HO-1 activity using the HO-1 inhibitor tin protoporphyrin IX (SnPPIX), resulted in loss of cytoprotection. Carbon monoxide, one of HO-1 catabolic products appeared to play a small role in CAPE protection. Caffeic acid, a potential metabolite of CAPE with similar free radical scavenging ability, however, didn't show any cytoprotective effect nor induce HO-1. These findings suggest an important role of HO-1 induction in CAPE cytoprotection against oxidant stress, which may not relate to CAPE structural antioxidant activity nor to its traditional enzymatic activity in decomposing heme but to a yet to be determined activity. Published by Elsevier B.V.

1. Introduction

Interruption in the flow of blood to a tissue leads to tissue ischemia, which is a major cause of morbidity and death contributing to disease processes such as heart disease, stroke, cancer, and traumatic injury. Failure to quickly reestablish flow to ischemic tissue results in tissue death, but even timely return to normal flow is detrimental because reintroduction of oxygen to ischemic tissue results in ischemia/reperfusion injury to the tissue. Caffeic acid phenethyl ester (CAPE), a plant-derived polyphenolic compound, has been shown to protect different organs from ischemia/reperfusion induced injury in various animal models (Ilhan et al., 1999; Esrefoglu et al., 2005; Ozer et al., 2005; Parlakpinar et al., 2005; Ozyurt et al., 2006).

CAPE, present in honeybee propolis, may be responsible for many biological activities including antitumor (Huang et al., 1996), antiviral (Fesen et al., 1994), immunomodulatory (Park et al., 2004), anti-inflammatory (Fitzpatrick et al., 2001), and antioxidant effects (Hsu et al., 2005). Recently, CAPE has been demonstrated to ameliorate ischemia/reperfusion injury *in vivo* in spinal cord (Ilhan et al., 1999),

E-mail address: phillip.bowman@amedd.army.mil (P.D. Bowman).

skeletal muscle (Ozyurt et al., 2006), and myocardium (Parlakpinar et al., 2005), and to protect remote organs such as testes and kidney from myocardial ischemia/reperfusion (Esrefoglu et al., 2005; Ozer et al., 2005). While its protective activity has been attributed to its known antioxidant ability, CAPE has also been shown to affect transcriptional activity, which may be similar to the cytoprotective effect of other polyphenolic antioxidants like curcumin and resveratrol (Chen et al., 2005; Motterlini et al., 2000; Scapagnini et al., 2002). The result presented here indicates that cytoprotection in human endothelial cells by CAPE involves transcriptional activation of heme oxygenase-1 (HO-1).

HO-1 is best known as the inducible isoform of heme oxygenase and the rate-limiting enzyme in the catabolism of heme into carbon monoxide (CO), biliverdin (which is rapidly converted to bilirubin by biliverdin reductase), and free iron (which is sequestered to ferritin, an iron-binding protein). HO-1 has been demonstrated to be a protective gene in various cell types due to its anti-inflammatory, anti-apoptotic and anti-proliferative properties (Lee et al., 1996; Willis et al., 1996; Brouard et al., 2000), which may support its role in attenuating ischemia/reperfusion injury. It has been reported that the induction of HO-1 or its heme-degrading products protect different organs from ischemia/reperfusion injury *in vivo* including gut, intestine, liver, kidney and heart (Akamatsu et al., 2004; Attuwaybi et al., 2004; Berberat et al., 2003; Clark et al., 2000; Fondevila et al., 2003; Hammerman et al.,

^{*} Corresponding author. US Army Institute of Surgical Research, 3400 Rawley E. Chambers Ave. Bldg. 3611, Fort Sam Houston, TX 78234-6315, USA. Tel.: +1 210 916 4297; fax: +1 210 916 2942.

maintaining the data needed, and c including suggestions for reducing	election of information is estimated to completing and reviewing the collect this burden, to Washington Headquuld be aware that notwithstanding aro OMB control number.	ion of information. Send comments arters Services, Directorate for Information	regarding this burden estimate mation Operations and Reports	or any other aspect of the , 1215 Jefferson Davis	nis collection of information, Highway, Suite 1204, Arlington	
1. REPORT DATE 04 SEP 2008		2. REPORT TYPE N/A		3. DATES COVE	RED	
4. TITLE AND SUBTITLE				5a. CONTRACT NUMBER		
Cytoprotection of human endothelial cells from menadione				5b. GRANT NUMBER		
by caffeic acid phenethyl ester: the role of heme oxygenase-1 6. AUTHOR(S)			5c. PROGRAM ELEMENT NUMBER			
			5d. PROJECT NUMBER			
Wang X., Stavchansky S., Zhao B., Bynum J. A., Kerwin S. M., Bowman P. D.,				5e. TASK NUMBER		
1. D.,			5f. WORK UNIT NUMBER			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX 78234				8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S AC			ONITOR'S ACRONYM(S)			
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAIL Approved for publ	LABILITY STATEMENT ic release, distributi	on unlimited				
13. SUPPLEMENTARY NO	OTES					
14. ABSTRACT						
15. SUBJECT TERMS						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF	18. NUMBER	19a. NAME OF	
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified	ABSTRACT UU	OF PAGES 8	RESPONSIBLE PERSON	

Report Documentation Page

Form Approved OMB No. 0704-0188 2002; Nakao et al., 2005; Salom et al., 2007). In addition, the "knocking down" of HO-1 exacerbated ischemia/reperfusion-induced lung and myocardial injury (Liu et al., 2005; Zhang et al., 2004). Recently, human HO-1 gene delivery using an adenovirus vector has been shown to be a feasible strategy for protecting heart, liver, and skeletal muscle in a rat ischemia/reperfusion model (Pachori et al., 2004). However, the requirement for production of heme-degrading products as the cytoprotective agents has recently been called into question (Hori et al., 2002; Sheftel et al., 2007).

Endothelial cells, which line all blood vessels, appear to play an important role during ischemia/reperfusion injury. They are known to respond to various stimuli, in part by changing the gene expression for cytokines, adhesion molecules, procoagulation factors, and other proteins (Granger et al., 2004; Minami et al., 2004). Our previous studies showed that CAPE protects human umbilical vein endothelial cells (HUVEC) against oxidative stress induced by menadione (Wang et al., 2006). As one of the simplest guinones, menadione has been widely studied as a model for evaluating the cellular effects of oxidative stress in endothelial cells, including induction of apoptosis (Kossenjans et al., 1996; Warren et al., 2000). The major mechanism of endothelial cell toxicity caused by menadione is the intracellular production of reactive oxygen species by redox cycling, where one electron reduction of O₂ by the semiguinone form of menadione generates superoxide. Superoxide dismutates to form hydrogen peroxide, which then participates in the Fenton reactions producing hydroxyl radicals. Because the generation of reactive oxygen species is a major outcome of ischemia/reperfusion injury, menadione-induced endothelial cell injury was used to simulate ischemia/reperfusion injury in vitro. The purpose of our present study was to investigate the mechanism of CAPE protection against reactive oxygen species-mediated injury in vitro. We hypothesized that heme oxygenase-1 induction is the key component in CAPE protection against oxidative stress.

2. Materials and methods

2.1. Materials

CAPE was purchased from Cayman Chemical (Ann Arbor, MI, USA). Caffeic acid, bilirubin, menadione sodium bisulfite (menadione), and DMSO were purchased from Sigma (Saint Louis, MO, USA). Biliverdin hydrochloride and Sn(IV) protoporphyrin IX dichloride (SnPPIX) were purchased from Frontier Scientific (Logan, UT, USA). 5-(and-6)-chlormethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H₂DCFDA) was obtained from Invitrogen (Carlsbad, CA, USA).

2.2. Cell culture

First passage HUVEC (Cascade Biologics, Portland, OR, USA) were cultivated on 1% gelatin-coated 75-cm² culture flasks (Corning Incorporated, Corning, NY, USA) in Medium 200 supplemented with 2% fetal calf serum, penicillin (100 units/ml), streptomycin (100 units/ml), and Fungizone (0.25 $\mu g/ml)$ supplied by Cascade Biologics (Zhao et al., 2001). The cells were cultivated at 37 °C in a humidified atmosphere of 95% air and 5% CO2 with medium changes every 2 days until confluent. Prior to an experiment, HUVEC were subcultivated with Trypsin/EDTA onto 1% gelatin-coated Costar® multiplates (Corning Incorporated, Corning, NY, USA) at 5000 cells/cm², grown to confluence, and kept for 72 h to produce a quiescent cell layer. On the day before the experiment, the medium was changed. Only the second through fifth population doublings of cells were used.

2.3. Cell viability assay

Cell viability was assessed at 24 h after initiation of treatment using Alamar Blue™ (Biosource International, Camarillo, CA, USA), which is converted to a fluorescent compound in amounts propor-

tional to the number of viable cells (Larson et al., 1997). The cells were incubated for 2 h at 37 °C with culture medium containing 10% Alamar BlueTM. After incubation, fluorescence was measured at 545 nm excitation and 590 nm emissions using SpectraMAX M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA). HUVEC were regularly observed under phase contrast microscopy.

2.4. Menadione cytotoxicity assay

Menadione bisulfite (0.5 M) was dissolved in phosphate buffered saline (PBS) (Gao et al., 2001) and diluted with medium before being added to the plate wells. Due to differences in cellular responses to menadione, each group of pooled HUVEC was initially assessed for a dose of menadione which is close to its toxicity producing 80–90% cell death. Cells were incubated in 5 to 38 μ M menadione depending on the sensitivity of a given set of cells for 24 h followed by Alamar Blue viability assay.

2.5. In vitro cytoprotection assay

CAPE, biliverdin, bilirubin, and caffeic acid were dissolved in DMSO and diluted 1000-fold with medium before addition of serial dilutions to the 48-well culture plates. To assess protection against oxidative stress, confluent HUVEC were initially pretreated with CAPE, biliverdin, bilirubin, and caffeic acid at various concentrations for 6 h, and the cytotoxic dose of menadione chosen from menadione cytotoxicity assay was then given to the HUVEC in the presence of testing compounds. After 24 h incubation, cell viability was measured using the Alamar Blue assay.

2.6. Total RNA isolation

Total RNA was extracted from cultured HUVEC grown in 6-well multiplates with TRI™ reagent according to the manufacture's instructions (Molecular Research Center, Cincinnati, OH, USA). RNA yield was quantified using NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and its quality was assessed by electrophoresis on 1% agarose gels containing 1:1000 SYBR Gold in the loading buffer (Invitrogen, Carlsbad, CA, USA).

2.7. Polyacrylamide gel electrophoresis, and western blotting

Protein was extracted from the HUVEC grown on gelatin coated 24well multiplates after incubation with CAPE (17.6 µM) for 24 h, by addition of 50 µl of lysis buffer (NOVEX, San Diego, CA, USA) containing 10 mM tris (carboxyethyl) phosphine hydrochloride (Sigma, St Louis, MO, USA). Fifteen microliters, containing approximately 5 µg of protein, from each treatment were run on NuPage 4-12% bis-tris gels (Invitrogen) and then transferred to a nitrocellulose membrane (Invitrogen). After blocking in 0.2% I-Block (Tropix, Bedford, MA, USA), 0.1% Tween-20 (Sigma) and 0.1% thimerosal (Sigma) in PBS, the blots were then incubated with a rabbit anti-rat HO-1 antibody (Assay Designs Inc., Ann Arbor, MI, USA; 1:5000) for 2 h. Rabbit ABC alkaline phosphatase reagents (Vector Laboratories, Burlingame, CA, USA) were used to label the bands and the alkaline phosphotase visualization was accomplished with nitro blue tetrazolium chloride (NBT) and 5-Bromo-4chloro-3-indolyl phosphate (BCIP) (Invitrogen) until the bands developed. Quantitative analysis was performed with NIH Images (NIH, USA) on blots scanned into the computer. Following staining for HO-1, blots were stripped and reprobed with mouse anti-actin (Abcam, Cambridge, MA, USA) as a control for equal loading of protein.

2.8. Gene expression analysis

Microarrays containing ~22,000 human genes per array were produced by spotting oligonucleotides (Qiagen/Operon Human

ArrayReady Oligo Set V 2.0, Alameda, CA, USA) onto epoxy-coated slides (Cel Associates, Pearland, TX, USA). A GeneMachines Omni Accent Gridder (GeneMachines, San Carlos, CA, USA) and SMP-3 pins from Telechem International (Sunnyvale, CA, USA) were applied to print the microarrays. Microarrays were blocked with 1% BSA in 3× SSC and 0.1% SDS for 1 h at 50 °C before use.


For gene expression analysis, RNA extracted from CAPE-treated (17.6 µM) and DMSO-treated HUVEC (0.1%) following a 6-h incubation were compared to human universal reference RNA (Stratagene, La Jolla, CA, USA). cDNA targets were generated with the 3DNA Array 900 kit (Genisphere Inc., Hatfield, PA, USA) according to the manufacture's instructions. The high-resolution scans (10 µm) were acquired with a GenePix scanner 4000B (Axon Instruments, Inc., Union City, CA, USA) and tabulated with GenePix pro 5.1 software. To determine intra-assay variability, each condition (3 replicates) was individually labeled and compared to a universal reference of pooled RNA that was labeled as a pool sufficient for 6 microarrays. Statistical analysis for differences between treatment groups was performed using BRB Array Tools (Biometric Research Branch, National Cancer Institute, USA, http://linus.nci.nih.gov/BRB-ArrayTools.html).

2.9. Quantitative real-time RT-PCR

One μg of total RNA from the same samples used for microarray analysis was converted to cDNA using random primers and Superscript III reverse transcriptase according to the manufacture's instruction (InvitrogenTM life Technology, Carlsbad, CA, USA). Real-time PCR was performed on a LightCyclerTM thermal cycler (Idaho Technology, Salt Lake City, UT, USA) with Roche LightCycler® TaqMan Master for heme oxygenase-1 and β -actin (Roche Diagnostics, Indianapolis, IN, USA). HO-1 and β -actin primer sets were from TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA, USA). HO-1 gene was

Table 1
CAPE-regulated significant alteration of gene expression in HUVEC

Detoxification Molecular Chaperone Heat shock protein 90 kDa beta (Grp94), member 1 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) Growth factor KIT ligand Prostate differentiation factor Endothelial cell-specific molecule 1 Solute carrier family 30 (zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated Selenoprotein K (selenium binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (P788 MAPK signaling pathway) Apoptosis BICL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Kinase Eukaryotic translation initiation factor 2-914 2-alpha kinase 3 Transferase Others Phorbol-12-descript 50B CDNA FLJ14162 fis, clone NTZRM4002504 2-696	Gene category	Gene description	Fold change
chaperone (Grp94), member 1 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) Growth factor KIT ligand 4.727 Prostate differentiation factor 4.625 Endothelial cell-specific molecule 1 2.878 Transporter Solute carrier family 3, member 2 3.187 Solute carrier family 30 2.492 (zinc transporter), member 1 Solute carrier family 39 2.834 (zinc transporter), member 14 START domain containing 4, sterol regulated 2.705 Binding Selenoprotein K (selenium binding) 3.399 Nucleobindin 2 (calcium ion binding) 3.146 Asp (abnormal spindle)-like 0.285 (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 2.508 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog 0.313 (S. cerevisiae) Transmembrane protein 50B 3.451	Detoxification	Heme oxygenase (decycling) 1	8.245
Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) Growth factor KIT ligand Prostate differentiation factor Endothelial cell-specific molecule 1 2.878 Transporter Solute carrier family 3, member 2 3.187 Solute carrier family 30 (zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated 2.705 Binding Selenoprotein K (selenium binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Sinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451	Molecular	Heat shock protein 90 kDa beta	2.832
(glucose-regulated protein, 78 kDa) Growth factor KIT ligand 4.727 Prostate differentiation factor 4.625 Endothelial cell-specific molecule 1 2.878 Transporter Solute carrier family 3, member 2 3.187 Solute carrier family 30 2.492 (zinc transporter), member 1 Solute carrier family 39 2.834 (zinc transporter), member 14 START domain containing 4, sterol regulated 2.705 Binding Selenoprotein K (selenium binding) 3.399 Nucleobindin 2 (calcium ion binding) 3.146 Asp (abnormal spindle)-like 0.285 (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 2.508 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog 0.313 (S. cerevisiae) Transmembrane protein 50B 3.451	chaperone	(Grp94), member 1	
Transcription STG family, member 2 2.572		Heat shock 70 kDa protein 5	3.954
Growth factor KIT ligand Prostate differentiation factor Endothelial cell-specific molecule 1 4.727 Transporter Solute carrier family 3, member 2 3.187 Solute carrier family 30 (zinc transporter), member 1 Solute carrier family 39 2.834 (zinc transporter), member 14 START domain containing 4, sterol regulated 2.705 Binding Selenoprotein K (selenium binding) 3.399 Nucleobindin 2 (calcium ion binding) 3.146 Asp (abnormal spindle)-like (calmodulin binding) 0.285 Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) 2.508 Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) 4.717 Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 3.490 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2-alpha kinase 3 2.914 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) 0.313 (S. cerevisiae)		(glucose-regulated protein,	
Prostate differentiation factor Endothelial cell-specific molecule 1 2.878 Transporter Solute carrier family 3, member 2 (zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated START domain spindle)-like (calmodulin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 SA490 interacting protein 3 Cytokine Interleukin 8 Sinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451		78 kDa)	
Endothelial cell-specific molecule 1 2.878 Transporter Solute carrier family 3, member 2 3.187 Solute carrier family 30 2.492 (zinc transporter), member 1 Solute carrier family 39 2.834 (zinc transporter), member 14 START domain containing 4, sterol regulated 2.705 Binding Selenoprotein K (selenium binding) 3.399 Nucleobindin 2 (calcium ion binding) 3.146 Asp (abnormal spindle)-like 0.285 (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 2.508 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog 0.313 (S. cerevisiae) Transmembrane protein 50B 3.451	Growth factor	KIT ligand	4.727
Transporter Solute carrier family 3, member 2 Solute carrier family 30 (zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated Sterol calcium ion binding) Sterol calcium ion binding) START domain spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 START domain spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 START domain spindle)-like (protein binding) START domain spindle START domain		Prostate differentiation factor	4.625
Solute carrier family 30 (zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated START domain spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 START demails, member 2 START demails, member 2 START demails, member 2 START demails, member 3 START de			2.878
(zinc transporter), member 1 Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated START domain containing 3.399 Nucleobindin 2 (calcium binding) Nucleobindin 2 (calcium ion binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Sudaportic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451	Transporter		3.187
Solute carrier family 39 (zinc transporter), member 14 START domain containing 4, sterol regulated START domain containing 3.399 Nucleobindin 2 (calcium ion binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 C.572 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Sudayotic translation initiation factor 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451		•	2.492
(zinc transporter), member 14 START domain containing 4, sterol regulated START domain containing 4, sterol regulated Selenoprotein K (selenium binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 regulator DNA-damage-inducible transcript 3 Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Siden Side			
START domain containing 4, sterol regulated Selenoprotein K (selenium binding) Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Kinase Eukaryotic translation initiation factor 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.450		•	2.834
Binding Selenoprotein K (selenium binding) 3.399 Nucleobindin 2 (calcium ion binding) 3.146 Asp (abnormal spindle)-like 0.285 (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 2.508 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog 0.313 (S. cerevisiae) Transmembrane protein 50B 3.451			
Nucleobindin 2 (calcium ion binding) Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 regulator DNA-damage-inducible transcript 3 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Sinase Eukaryotic translation initiation factor 2-914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			2.705
Asp (abnormal spindle)-like (calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 2.508 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451	Binding		3.399
(calmodulin binding) Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) BTG family, member 2 2.572 Phorbol-12-myristate-13-acetate-induced protein 1 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
Phorbol-12-myristate-13-acetate-induced protein 1 (protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451		1 '	0.285
(protein binding) Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
Transcription BTG family, member 2 2.572 regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			2.508
regulator DNA-damage-inducible transcript 3 4.717 (P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa 3.490 interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
(P38 MAPK signaling pathway) Apoptosis BCL2/adenovirus E1B 19 kDa		3.	
Apoptosis BCL2/adenovirus E1B 19 kDa interacting protein 3 Cytokine Interleukin 8 Kinase Eukaryotic translation initiation factor 2-alpha kinase 3 Transferase Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.490 3.479 2.914 2-alpha kinase 3 Cytokine 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 01313 01313 01313 01313 01313	regulator		4.717
interacting protein 3 Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
Cytokine Interleukin 8 3.479 Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451	Apoptosis		3.490
Kinase Eukaryotic translation initiation factor 2.914 2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
2-alpha kinase 3 Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (S. cerevisiae) Transmembrane protein 50B 3.451			
Transferase Phosphatidylinositol glycan, class A 2.942 Others Spindle pole body component 25 homolog (3.313 (S. cerevisiae) Transmembrane protein 50B 3.451	Kinase	· ·	2.914
Others Spindle pole body component 25 homolog 0.313 (S. cerevisiae) Transmembrane protein 50B 3.451		*	
(S. cerevisiae) Transmembrane protein 50B 3.451			
Transmembrane protein 50B 3.451	Others		
CDNA FLJ14162 fis, clone NT2RM4002504 2.696			
		CDNA FLJ14162 fis, clone NT2RM4002504	2.696



*: P<0.05 versus control (menadione at 0 μM).

Fig. 1. Toxicity of menadione in HUVEC. Menadione caused a dose-dependent reduction of viability in HUVEC. Values are presented as means with standard deviations (n=3). The dose of menadione at 25 μ M was used in the CAPE cytoprotection assay.

normalized to the expression level of β -actin gene for each sample. Relative quantification was acquired by comparative C_T method.

2.10. Heme oxygenase-1 inhibition with SnPPIX


HUVEC were pretreated with 17.6 µM CAPE and different doses of HO-1 inhibitor SnPPIX (Abuarqoub et al., 2006), respectively, for 6 h before exposing to menadione for 24 h. SnPPIX was dissolved in 0.1 M NaOH and dilute 1000-fold with medium before being added to the 48-well culture plates. Cell viability was measured using the Alamar Blue assay.

2.11. Carbon monoxide exposure

HUVEC were exposed to 1% CO and 5% CO₂ in air (Matheson-TriGas, Kyle, TX, USA) in sealed incubator chambers (Billups-Rothenberg Inc, Del Mar, CA, USA). Cultures identically treated but exposed to 95% air 5% CO₂ served as control. After a 10-min purging of either CO or air, HUVEC were incubated for 2 h. Various concentrations of menadione were then added to the culture media and the culture plates were returned to the chambers. After 10 min of purging with 1% CO or air, HUVEC were incubated for additional 24 h in sealed chambers. The cell culture chambers were humidified and maintained at 37 °C. Cell viability was measured using the Alamar Blue assay.


2.12. Assay for measuring reactive oxygen species

Intracellular production of reactive oxygen species was evaluated by exposing HUVEC to 20 μ M CAPE, caffeic acid, or 0.1% DMSO and



*: P<0.001 versus vehicle control.

Fig. 2. Cytotoxicity of CAPE to HUVEC. Values are presented as means with standard deviations (n=3). Cell viability is shown as percent of control, and less than 90% was considered toxic. Therefore, CAPE at 52.8 μM was considered toxic.



*: P<0.05 versus 25 µM menadione alone (CAPE at 0 µM).

Fig. 3. Cytoprotection against menadione-induced injury in HUVEC by CAPE. Menadione was used at $25 \,\mu$ M. Values are presented as means with standard deviations (n=3). CAPE showed dose-dependent cytoprotection against menadione. CAPE at 17.6 μ M recovered HUVEC significantly to about 65% from menadione-induced injury (P=0.001).

fluorescent probe 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H₂DCFDA) (Jones et al., 2002). HUVEC were seeded onto 96-well plates and grown to confluence. HUVEC were rinsed twice with prewarmed Hanks' HEPES buffer prepared with Hanks' balanced salt solution (without sodium bicarbonate or phenol red; Invitrogen) and 10 mM HEPES buffer (Sigma), and incubated for 30 min at 37 °C in the same solution with CM-H₂DCFDA (8 μM) premixed in Hanks' HEPES buffer. HUVEC were then washed twice with prewarmed Hanks' HEPES buffer and loaded with the testing compounds dissolved in Hanks' HEPES buffer. The fluorescence released from the cells was recorded immediately at 480 nm (excitation) and 520 nm (emission) using SpectraMAX M2 microplate reader at different time intervals over a 2-h period while the HUVEC were incubated at 37 °C within the plate reader. The fluorescent signals were normalized to the initial readings at time zero. The relative fluorescence was proportional to the production of reactive oxygen species.

2.13. Statistical analysis

Data are presented as the mean \pm standard deviation. Differences between or among the groups were analyzed using the independent samples T test or one-way analysis of variance combined with Tukey (equal variances assumed) or Games-Howell (equal variances not assumed) test through SPSS statistical software. A difference of p value < 0.05 was considered significant. Each experiment was repeated at least 3 times and a representative experiment is presented.




Fig. 4. Heme oxygenase-1 gene induction by CAPE and caffeic acid in HUVEC by relative quantitative real-time RT-PCR. Heme oxygenase-1 expression was highly increased (29-fold) in CAPE group compared to DMSO control. Caffeic acid group didn't induce HO-1 significantly compared to the control group. Values are presented as means with standard deviations (n=3).




Fig. 5. Effect of CAPE on HO-1 protein expression in HUVEC by western blot. The induction of HO-1 protein was determined in HUVEC after incubating with 17.6 μ M CAPE and DMSO control for 24 h.


For microarray analysis with BRB Array Tools, genes were excluded if flagged. After lowess smooth normalization, a two-class comparison was performed to identify genes that were differentially expressed using a random-variance t-test. Genes were considered to be significantly altered in their expression if the P value<0.001. The common genes significantly up-regulated between two independent experiments were identified by intersecting the two individual genelists in BRB Array Tools. The mean fold changes from two independent experiments are presented in Table 1. The series of datasets discussed herein can be accessed at the Gene Expression Omnibus (GEO) website under the submission number GSE10465 which includes two subset series (GSE10413 and GSE10429) corresponding to two independent experiments (http://www.ncbi.nlm.nih.gov/geo/).

3. Results

3.1. Protective effects of CAPE against menadione-induced oxidative stress in human endothelial cells


The oxidant stress model of HUVEC produced by menadionegenerated reactive oxygen species is shown in Fig. 1. Menadione induced a dose-dependent decrease in the viability of HUVEC as demonstrated by the Alamar Blue assay.


CAPE cytotoxicity was examined at 17.6, 35.2, and 52.8 μ M and is shown in Fig. 2. Because 52.8 μ M of CAPE caused more than 10% cell death, the maximum dose of CAPE used for cytoprotection testing was 35.2 μ M. CAPE protected HUVEC against menadione-induced ischemia/reperfusion-like injury in a dose-dependent fashion (Fig. 3). At 17.6 μ M, CAPE had the maximum cytoprotective effect against menadione-induced toxicity, showing 65% HUVEC recovery compared to about 15% cell viability after menadione exposure alone.



- *: P<0.01 versus CAPE + MD alone.
- ♣: P<0.001 versus MD alone.

Fig. 6. The effect of HO-1 inhibitor SnPPIX on 17.6 μM CAPE cytoprotection against menadione (MD)-mediated oxidative injury in HUVEC. Values are presented as means with standard deviations (n=3). SnPPIX exerted dose-dependent suppression on 17.6 μM CAPE protection against 25 μM MD-induced oxidative injury. CAPE plus 30 μM SnPPIX alone was not toxic.






♣: P<0.01 versus MD alone.</p>

Fig. 7. Cytoprotective effects of biliverdin (A) and bilirubin (B) testing compared to 17.6 μ M CAPE in HUVEC against oxidative stress induced by 30 μ M menadione (MD). Values are presented as means with standard deviations (n=3). Neither biliverdin nor bilirubin from 0.01 μ M to 1 μ M demonstrated protection.

3.2. Heme oxygenase-1 induction by CAPE in HUVEC

To investigate the mechanism behind CAPE cytoprotection at the transcriptional level, gene expression analysis was performed using oligonucleotide microarrays. Of the 22,000 human genes examined from two independent experiments, 23 genes were statistically significantly up-regulated during the early response (6 h) to CAPE (Table 1). Among them, HO-1 was highly induced (8.25-fold) by CAPE compared to DMSO control. To validate this particular microarray



*: P<0.01 versus no CO control at the same dose of menadione.

Fig. 8. The cytoprotective effect of 1% CO against low doses of menadione-induced oxidative damage in HUVEC. Values are represented as means with standard deviation (n=3). About 20% more cell viability was observed in 1% CO-treated HUVEC (black-spot filled column) than control (white column).




Fig. 9. Cytoprotective activities of caffeic acid versus CAPE at 20 µM in 22.5 µM menadione (MD)-treated HUVEC. Values are represented as means with standard deviations (*n*=3). Caffeic acid was not cytoprotective in HUVEC against MD-induced cytotoxicity.

screening result, quantitative real-time RT-PCR was performed at 6 h and western blotting was performed for HO-1 at 24 h. The results confirmed that the HO-1 gene was upregulated about 29-fold (Fig. 4) while its protein product was elevated about 6-fold (Fig. 5).

3.3. Heme oxygenase-1 inhibitor SnPPIX effects on CAPE cytoprotection

To test whether the cytoprotective effects of CAPE were dependent on HO-1 activity, HO-1 activity was blocked by its competitive inhibitor SnPPIX. Coincubating with varying concentrations of SnPPIX and 17.6 μ M CAPE resulted in reduction of cytoprotection against menadione dose-dependently (Fig. 6).

3.4. The effects of biliverdin and bilirubin

To further elucidate the role of HO-1 in CAPE cytoprotection, we tested heme catabolism products biliverdin and bilirubin. They have been reported to be potent antioxidants against peroxyl radicals (Stocker et al., 1987), which may contribute to the protective effect of HO-1. In this study, biliverdin and bilirubin ranging from 0.01 μ M to 1 μ M showed no protective effect (Fig. 7), and these doses did not appear to be toxic alone in HUVEC (data not shown).

3.5. The effects of carbon monoxide

To determine if CO could account for the cytoprotective effect of HO-1, HUVEC were exposed to various concentrations of menadione in the presence or absence of 1% CO and cell viability assessed by the Alamar Blue assay. Cells in the presence of CO showed better survivability at low doses of menadione (5–10 μ M) (Fig. 8).




Fig. 10. Direct antioxidant effect of CAPE and caffeic acid at 20 μM on intracellular production of reactive oxygen species (ROS). Values are represented as means with standard deviations (n=4). Both CAPE and caffeic acid served as antioxidants by reducing the basal level of reactive oxygen species in 2 h due to their structural-related free radical scavenging abilities.

3.6. The effect of caffeic acid with similar structural antioxidant activity to CAPE

The structural feature responsible for the free radical scavenging activities of CAPE is the two adjacent hydroxyl groups on its catechol moiety (Chen and Ho, 1997). We asked if the beneficial effect of CAPE was shared by caffeic acid, a potential metabolite of CAPE with the same antioxidant functional group. The data in Fig. 9 showed no cytoprotective effect of caffeic acid compared to CAPE at the same molar amount (20 μ M). RT-PCR data indicated that HO-1 was not induced by caffeic acid either (Fig. 4). The determination of intracellular generation of reactive oxygen species indicated that both CAPE and caffeic acid behaved as similarly as antioxidants in HUVEC scavenging free radicals (Fig. 10).

4. Discussion

Ischemia/reperfusion injury occurs in cardiovascular disease, surgical procedures, organ transplantations and following traumatic injury. The human endothelial cell plays an important role in this type of injury and it is important to protect it from further dysfunction and restore its normal function as soon as possible after injury. Polyphenolic compounds such as CAPE may provide some amelioration of ischemia/reperfusion injury at the level of the endothelial cells. To better understand the potential protective mechanism of CAPE, we developed an in vitro model of menadione-induced oxidative stress in HUVEC. This study demonstrated that CAPE provided dose-dependent cytoprotection of HUVEC against menadione-caused oxidative injury. The antioxidant activity of CAPE has been proposed to account for its beneficial effect in ischemia/reperfusion injury (Esrefoglu et al., 2005; Ilhan et al., 1999; Ozer et al., 2005; Ozyurt et al., 2006; Parlakpinar et al., 2005). As a polyphenolic compound, CAPE maintains the catechol ring with 3,4-dihydroxyl configuration, which can directly scavenge free radicals. In addition, CAPE may also exert its protective effect via transcriptional activation as do some other polyphenols (Chen et al., 2005; Motterlini et al., 2000; Scapagnini et al., 2002). To investigate its mechanism of cytoprotection at the transcriptional level, gene expression analysis was performed. It was determined that HO-1 was highly induced by CAPE in HUVEC with confirmation by RT-PCR and western blot.

HO-1 induction has been shown to be beneficial in ischemia/ reperfusion injury in vivo (Pachori et al., 2004; Salom et al., 2007). Several mechanisms of HO-1 protection against ischemia/reperfusion injury have been proposed: 1) metabolism of heme, the toxic cellular component from disposed heme proteins; 2) consumption of excessive O₂ during ischemia/reperfusion injury in the process of heme degradation by HO-1; and 3) cytoprotection through heme catabolizing products such as biliverdin/bilirubin, ferrous iron/ferritin, and carbon monoxide (Katori et al., 2002). To further elucidate the role of HO-1 induction in CAPE cytoprotection, HO-1 activity was suppressed by using HO-1 inhibitor SnPPIX. The cytoprotective effect of CAPE against menadione-induced cytotoxicity was abrogated in a concentration-dependent fashion with the co-incubation of non-toxic doses of SnPPIX. This result indicated that HO-1 induction plays an important role in CAPE cytoprotection. Since heme degradation by HO-1 results in biliverdin, bilirubin, and CO production and all have been reported to ameliorate ischemia/reperfusion induced injury in different organs in vivo (Akamatsu et al., 2004; Clark et al., 2000; Fondevila et al., 2003; Hammerman et al., 2002), we examined their cytoprotective activities. BR as low as 10 nM can protect cells against oxidative stress induced by 100 µM hydrogen peroxide, which seems to function through the conversion from biliverdin to bilirubin by the action of biliverdin reductase (Baranano et al., 2002). Therefore, we tested the cytoprotective effects of biliverdin to bilirubin ranging from 0.01 to 1 μM, but no protection was observed compared to CAPE. Generation of CO by HO-1 might explain CAPE cytoprotection evidenced from the suppression of endothelial cell apoptosis by 1% exogenous CO exposure (Brouard et al., 2000). Mishra recently reported that carbon monoxide provided cytoprotection in ischemic lungs by interrupting mitogen activated protein kinase expression of early growth response1 genes and their downstream target genes (Mishra et al., 2006). The observation that 1% CO only provided some protection at low doses of menadione challenge but not at higher doses (data not shown) plus the fact that no cytoprotective effect showed for biliverdin to bilirubin needs further investigation. One possibility is that delivering carbon monoxide in the environment rather than generating it intracellularly in the appropriate compartment as does heme oxygenase-1 may explain the fact that we did not obtain as complete a cytoprotective effect as compared to CAPE.

Many biological activities of polyphenols have been ascribed to their antioxidant properties. The 3,4 dihydroxyl configuration on the catechol ring of CAPE and similar polyphenolic compounds provides the key functional group for their free radical scavenging activity. Caffeic acid, a precursor and potential degradation product of CAPE, has been shown to possess similar antioxidant and free radical scavenging activities evaluated by three different methods including inhibitory effect on lipid oxidation by the rancimat method, scavenging effect on 2,2-diphenyl-L-picrylhydrazyl radicals, and antioxidative effect in oil-in-water emulsion (Chen and Ho, 1997). This was also confirmed with our cell-based antioxidant assay, showing CAPE and caffeic acid both reduced the basal intracellular level of reactive oxygen species to a significant level in 2 h. The result that caffeic acid showed no significant cytoprotection against menadione compared to CAPE indicates the transcription activity of these compounds may be more important than their direct antioxidant effect.

The HO-1 activation by plant-derived polyphenolic antioxidants has been observed in human smooth muscle cells by resveratrol (Juan et al., 2005), PC12 cells by carnosol (Martin et al., 2004), renal epithelial cells and endothelial cell by curcumin (Balogun et al., 2003; Motterlini et al., 2000). CAPE has also been identified as a HO-1 inducer in astrocytes (Scapagnini et al., 2002). The results reported here show that CAPE induces HO-1 in human endothelial cells. The major signaling transduction involved in HO-1 induction by those electrophilic polyphenolic compounds has been attributed to the activation of NF-E2 related factor-2 (Nrf2). Under normal conditions, Nrf2 is inactive in cytoplasm because it is bound to Keap 1. It has been suggested that these polyphenolic antioxidants interact with the thiol groups of Keap1, which releases Nrf2 from Nrf2/Keap1 complex. The free Nrf2 is subsequently translocated into the nucleus, where it forms heterodimers with small Maf, then binds to the antioxidant response element (ARE), and accelerates the transcription of HO-1 (Dinkova-Kostova et al., 2002). The activation of the Keap1/Nrf2/ARE pathway has been proposed to mediate the induction of other phase II detoxifying enzymes in addition to HO-1 including NAD(P)H: quinone oxidoreductase 1 and Glutathione S-transferases (Dinkova-Kostova et al., 2001). However, the gene response in HUVEC regulated by CAPE during the 6-h induction period didn't show any phase II genes induction other than HO-1 (Table 1). Although HO-1 up-regulation itself is sufficient to provide protection against oxidative stress (Otterbein et al., 2003), we cannot exclude the possibility that other detoxifying genes might be expressed earlier or later and exert protective effects.

However, a variety of other inducers of HO-1 chemically unrelated to polyphenols have been described (Kronke et al., 2003, 2007; Loboda et al., 2005; Prawan et al., 2008) and the mechanism of cytoprotection by way of biliverdin/bilirubin and carbon monoxide has come into question. Sheftel et al. (2007) have noted that nonheme inducers do not typically result in increases in intracellular ferritin as they do not provide a substrate for it and yet enzymatically inactive HO-1 transfected cells conferred cytoprotection (Hori et al., 2002). Lin et al. (2007) suggested that HO-1 may have the capacity to act as a transcription factor after its induction as it could be proteolytically

processed and translocated into the nucleus following synthesis. Some of the other genes upregulated by CAPE i.e. hsp70 and hsp90 that have been correlated with cytoprotection might be the actual protectants. Whether similar effects of HO-1 in human endothelial cells account for its cytoprotective effects is currently unknown.

In conclusion, the cytoprotective effect of CAPE in human endothelial cells, in large part, resulted from its transcriptional activities, mainly the induction of HO-1, rather than its structure-related antioxidant activity as caffeic acid exhibited good antioxidant activity but was not cytoprotective. The mechanism by which this relatively specific induction of HO-1 by CAPE in human endothelial cells is not entirely clear and may result from phosphorylation or other signaling events that are independent of the activation of the antioxidant response element that is commonly known to regulate the phase II response.

References

- Abuarqoub, H., Foresti, R., Green, C.J., Motterlini, R., 2006. Heme oxygenase-1 mediates the anti-inflammatory actions of 2'-hydroxychalcone in RAW 264.7 murine macrophages. American Journal of Physiology. Cell Physiology 290, C1092–1099.
- Akamatsu, Y., Haga, M., Tyagi, S., Yamashita, K., Graca-Souza, A.V., Ollinger, R., Czismadia, E., May, G.A., Ifedigbo, E., Otterbein, L.E., Bach, F.H., Soares, M.P., 2004. Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J. 18, 771–772.
- Attuwaybi, B.O., Kozar, R.A., Moore-Olufemi, S.D., Sato, N., Hassoun, H.T., Weisbrodt, N.W., Moore, F.A., 2004. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. Journal of Surgical Research 118, 53–57.
- Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., Alam, J., Motterlini, R., 2003. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochemical Journal 371, 887–895.
- Baranano, D.E., Rao, M., Ferris, C.D., Snyder, S.H., 2002. Biliverdin reductase: a major physiologic cytoprotectant. Proceedings of the National Academy of Sciences of the United States of America 99, 16093–16098.
- Berberat, P.O., Katori, M., Kaczmarek, E., Anselmo, D., Lassman, C., Ke, B., Shen, X., Busuttil, R.W., Yamashita, K., Csizmadia, E., Tyagi, S., Otterbein, L.E., Brouard, S., Tobiasch, E., Bach, F.H., Kupiec-Weglinski, J.W., Soares, M.P., 2003. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J. 17, 1724–1726.
- Brouard, S., Otterbein, L.E., Anrather, J., Tobiasch, E., Bach, F.H., Choi, A.M., Soares, M.P., 2000. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. Journal of Experimental Medicine 192, 1015–1026.
- Chen, J.H., Ho, C.T., 1997. Antioxidant activities of caffeic acid and its related hydroxycinnamic acid compounds. Journal of Agricultural and Food Chemistry 45, 2374–2378.
- Chen, C.Y., Jang, J.H., Li, M.H., Surh, Y.J., 2005. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochemical and Biophysical Research Communications 331, 993–1000.
- Clark, J.E., Foresti, R., Sarathchandra, P., Kaur, H., Green, C.J., Motterlini, R., 2000. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. American Journal of Physiology 278, H643–651.
- Dinkova-Kostova, A.T., Massiah, M.A., Bozak, R.E., Hicks, R.J., Talalay, P., 2001. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proceedings of the National Academy of Sciences of the United States of America 98, 3404–3409.
- Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., Talalay, P., 2002. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America 99, 11908–11913.
- Esrefoglu, M., Gul, M., Parlakpinar, H., Acet, A., 2005. Effects of melatonin and caffeic acid phenethyl ester on testicular injury induced by myocardial ischemia/reperfusion in rats. Fundamental & Clinical Pharmacology 19, 365–372.
- Fesen, M.R., Pommier, Y., Leteurtre, F., Hiroguchi, S., Yung, J., Kohn, K.W., 1994. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochemical Pharmacology 48, 595–608.
- Fitzpatrick, L.R., Wang, J., Le, T., 2001. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. Journal of Pharmacology and Experimental Therapeutics 299, 915–920.
- Fondevila, C., Katori, M., Lassman, C., Carmody, I., Busuttil, R.W., Bach, F.H., Kupiec-Weglinski, J.W., 2003. Biliverdin protects rat livers from ischemia/reperfusion injury. Transplantation Proceedings 35, 1798–1799.
- Gao, X., Dinkova-Kostova, A.T., Talalay, P., 2001. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proceedings of the National Academy of Sciences of the United States of America 98, 15221–15226.
- Granger, D.N., Vowinkel, T., Petnehazy, T., 2004. Modulation of the inflammatory response in cardiovascular disease. Hypertension 43, 924–931.

- Hammerman, C., Goldschmidt, D., Caplan, M.S., Kaplan, M., Bromiker, R., Eidelman, A.I., Gartner, L.M., Hochman, A., 2002. Protective effect of bilirubin in ischemia-reperfusion injury in the rat intestine. Journal of Pediatric Gastroenterology and Nutrition 35, 344–349
- Hori, R., Kashiba, M., Toma, T., Yachie, A., Goda, N., Makino, N., Soejima, A., Nagasawa, T., Nakabayashi, K., Suematsu, M., 2002. Gene transfection of H25A mutant heme oxygenase-1 protects cells against hydroperoxide-induced cytotoxicity. The Journal of Biological Chemistry 277, 10712–10718.
- Hsu, L.Y., Lin, C.F., Hsu, W.C., Hsu, W.L., Chang, T.C., 2005. Evaluation of polyphenolic acid esters as potential antioxidants. Biological & Pharmaceutical Bulletin 28, 1211–1215.
- Huang, M.T., Ma, W., Yen, P., Xie, J.G., Han, J., Frenkel, K., Grunberger, D., Conney, A.H., 1996. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 17, 761–765.
- Ilhan, A., Koltuksuz, U., Ozen, S., Uz, E., Ciralik, H., Akyol, O., 1999. The effects of caffeic acid phenethyl ester (CAPE) on spinal cord ischemia/reperfusion injury in rabbits. European Journal of Cardio-Thoracic Surgery 16, 458–463.
- Jones, W., Li, X., Qu, Z.C., Perriott, L., Whitesell, R.R., May, J.M., 2002. Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radical Biology & Medicine 33, 83–93.
- Juan, S.H., Cheng, T.H., Lin, H.C., Chu, Y.L., Lee, W.S., 2005. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochemical Pharmacology 69, 41–48.
- Katori, M., Anselmo, D.M., Busuttil, R.W., Kupiec-Weglinski, J.W., 2002. A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system. Transplant Immunology 9, 227–233.
- Kossenjans, W., Rymaszewski, Z., Barankiewicz, J., Bobst, A., Ashraf, M., 1996. Menadione-induced oxidative stress in bovine heart microvascular endothelial cells. Microcirculation 3, 39–47.
- Kronke, G., Bochkov, V.N., Huber, J., Gruber, F., Bluml, S., Furnkranz, A., Kadl, A., Binder, B.R., Leitinger, N., 2003. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. The Journal of Biological Chemistry 278, 51006–51014.
- Kronke, G., Kadl, A., Ikonomu, E., Bluml, S., Furnkranz, A., Sarembock, I.J., Bochkov, V.N., Exner, M., Binder, B.R., Leitinger, N., 2007. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 27, 1276–1282.
- Larson, E.M., Doughman, D.J., Gregerson, D.S., Obritsch, W.F., 1997. A new, simple, nonradioactive, nontoxic in vitro assay to monitor corneal endothelial cell viability. Investigative Ophthalmology & Visual Science 38, 1929–1933.
- Lee, P.J., Alam, J., Wiegand, G.W., Choi, A.M., 1996. Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. Proceedings of the National Academy of Sciences of the United States of America 93, 10393–10398.
- Lin, Q., Weis, S., Yang, G., Weng, Y.H., Helston, R., Rish, K., Smith, A., Bordner, J., Polte, T., Gaunitz, F., Dennery, P.A., 2007. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. The Journal of Biological Chemistry 282, 20621–20633.
- Liu, X., Wei, J., Peng, D.H., Layne, M.D., Yet, S.F., 2005. Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice. Diabetes 54, 778–784.
- Loboda, A., Jazwa, A., Wegiel, B., Jozkowicz, A., Dulak, J., 2005. Heme oxygenase-1-dependent and -independent regulation of angiogenic genes expression: effect of cobalt protoporphyrin and cobalt chloride on VEGF and IL-8 synthesis in human microvascular endothelial cells. Cellular and Molecular Biology (Noisy-le-Grand, France) 51, 347–355.
- Martin, D., Rojo, A.I., Salinas, M., Diaz, R., Gallardo, G., Alam, J., De Galarreta, C.M., Cuadrado, A., 2004. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. The Journal of Biological Chemistry 279, 8919–8929.
- Minami, T., Sugiyama, A., Wu, S.Q., Abid, R., Kodama, T., Aird, W.C., 2004. Thrombin and phenotypic modulation of the endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology 24, 41–53.
- Mishra, S., Fujita, T., Lama, V.N., Nam, D., Liao, H., Okada, M., Minamoto, K., Yoshikawa, Y., Harada, H., Pinsky, D.J., 2006. Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes. Proceedings of the National Academy of Sciences of the United States of America 103, 5191–5196.
- Motterlini, R., Foresti, R., Bassi, R., Green, C.J., 2000. Curcumin, an antioxidant and antiinflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radical Biology & Medicine 28, 1303–1312.
- Nakao, A., Neto, J.S., Kanno, S., Stolz, D.B., Kimizuka, K., Liu, F., Bach, F.H., Billiar, T.R., Choi, A.M., Otterbein, L.E., Murase, N., 2005. Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. American Journal of Transplantation 5, 282–291.
- Otterbein, L.E., Soares, M.P., Yamashita, K., Bach, F.H., 2003. Heme oxygenase-1: unleashing the protective properties of heme. Trends in Immunology 24, 449–455.
- Ozer, M.K., Parlakpinar, H., Vardi, N., Cigremis, Y., Ucar, M., Acet, A., 2005. Myocardial ischemia/reperfusion-induced oxidative renal damage in rats: protection by caffeic acid phenethyl ester (CAPE). Shock 24, 97–100.
- Ozyurt, B., Iraz, M., Koca, K., Ozyurt, H., Sahin, S., 2006. Protective effects of caffeic acid phenethyl ester on skeletal muscle ischemia-reperfusion injury in rats. Molecular and Cellular Biochemistry 292, 197–203.
- Pachori, A.S., Melo, L.G., Hart, M.L., Noiseux, N., Zhang, L., Morello, F., Solomon, S.D., Stahl, G.L., Pratt, R.E., Dzau, V.J., 2004. Hypoxia-regulated therapeutic gene as a

- preemptive treatment strategy against ischemia/reperfusion tissue injury. Proceedings of the National Academy of Sciences of the United States of America 101, 12282-12287.
- Park, J.H., Lee, J.K., Kim, H.S., Chung, S.T., Eom, J.H., Kim, K.A., Chung, S.J., Paik, S.Y., Oh, H.Y., 2004. Immunomodulatory effect of caffeic acid phenethyl ester in Balb/c mice. International Immunopharmacology 4, 429–436.
- Parlakpinar, H., Sahna, E., Acet, A., Mizrak, B., Polat, A., 2005. Protective effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia-reperfusion-induced apoptotic cell death. Toxicology 209, 1-14.
- Prawan, A., Keum, Y.S., Khor, T.O., Yu, S., Nair, S., Li, W., Hu, L., Kong, A.N., 2008. Structural influence of isothiocyanates on the antioxidant response element (ARE)-mediated heme oxygenase-1 (HO-1) expression. Pharmaceutical Research 225, 836–844.
- Salom, M.G., Ceron, S.N., Rodriguez, F., Lopez, B., Hernandez, I., Martinez, I.G., Losa, A.M., Fenoy, F.J., 2007. Heme oxygenase-1 induction improves ischemic renal failure: role of nitric oxide and peroxynitrite. American Journal of Physiology 293, H3542-3549
- Scapagnini, G., Foresti, R., Calabrese, V., Giuffrida Stella, A.M., Green, C.J., Motterlini, R., 2002. Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Molecular Pharmacology 61, 554-561.

- Sheftel, A.D., Kim, S.F., Ponka, P., 2007, Non-heme induction of heme oxygenase-1 does not alter cellular iron metabolism. The Journal of Biological Chemistry 282, 10480-10486.
- Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N., Ames, B.N., 1987, Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043–1046. Wang, X., Stavchansky, S., Bowman, P.D., Kerwin, S.M., 2006. Cytoprotective effect of
- caffeic acid phenethyl ester (CAPE) and catechol ring-fluorinated CAPE derivatives against menadione-induced oxidative stress in human endothelial cells. Bioorganic & Medicinal Chemistry 14, 4879–4887.

 Warren, M.C., Bump, E.A., Medeiros, D., Braunhut, S.J., 2000. Oxidative stress-induced
- apoptosis of endothelial cells. Free Radical Biology & Medicine 29, 537–547.
 Willis, D., Moore, A.R., Frederick, R., Willoughby, D.A., 1996. Heme oxygenase: a novel
- target for the modulation of the inflammatory response. Nature Medicine 2, 87–90.
- Zhang, X., Shan, P., Jiang, D., Noble, P.W., Abraham, N.G., Kappas, A., Lee, P.J., 2004. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. The Journal of Biological Chemistry 279, 10677–10684.
- Zhao, B., Bowden, R.A., Stavchansky, S.A., Bowman, P.D., 2001. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. American Journal of Physiology. Cell Physiology 281, C1587-1595.